Gulieva R, Ahmadvand P, Freedman B
Stem Cell Reports. 2025; 20(2):102395.
PMID: 39855202
PMC: 11864154.
DOI: 10.1016/j.stemcr.2024.102395.
Jobu Y, Nishigawa M, Furihata K, Furihata M, Uchida K, Taniuchi K
Hum Cell. 2025; 38(2):44.
PMID: 39794664
PMC: 11723851.
DOI: 10.1007/s13577-024-01165-9.
Lungu C, Creteanu A, Mehedinti M
Life (Basel). 2024; 14(4).
PMID: 38672722
PMC: 11051410.
DOI: 10.3390/life14040451.
Gianessi L, Magini A, Dominici R, Giovagnoli S, Dolcetta D
Int J Mol Sci. 2023; 24(24).
PMID: 38139306
PMC: 10744130.
DOI: 10.3390/ijms242417478.
Turolo S, Edefonti A, Syren M, Montini G
J Clin Med. 2023; 12(13).
PMID: 37445489
PMC: 10342352.
DOI: 10.3390/jcm12134454.
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors.
Burnett G, Yang Y, Aggen J, Pitzen J, Gliedt M, Semko C
J Med Chem. 2022; 66(1):149-169.
PMID: 36533617
PMC: 9841523.
DOI: 10.1021/acs.jmedchem.2c01658.
Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?.
Yi Y, You K, Park J, Lee S, Seong Y
Int J Mol Sci. 2022; 23(1).
PMID: 35008473
PMC: 8744729.
DOI: 10.3390/ijms23010048.
Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica.
Kangussu-Marcolino M, Singh U
Antimicrob Agents Chemother. 2021; 66(2):e0120721.
PMID: 34871094
PMC: 8846492.
DOI: 10.1128/AAC.01207-21.
PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism.
Simula L, Antonucci Y, Scarpelli G, Cancila V, Colamatteo A, Manni S
Mol Oncol. 2021; 16(1):188-205.
PMID: 34535949
PMC: 8732338.
DOI: 10.1002/1878-0261.13103.
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.
You K, Yi Y, Cho J, Park J, Seong Y
Pharmaceuticals (Basel). 2021; 14(6).
PMID: 34207383
PMC: 8233743.
DOI: 10.3390/ph14060589.
Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review.
Marlevi D, Edelman E
J Am Coll Cardiol. 2021; 77(19):2413-2431.
PMID: 33985687
PMC: 8238531.
DOI: 10.1016/j.jacc.2021.03.307.
Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia.
Kangussu-Marcolino M, Ehrenkaufer G, Chen E, Debnath A, Singh U
Int J Parasitol Drugs Drug Resist. 2019; 11:80-94.
PMID: 31707263
PMC: 6849155.
DOI: 10.1016/j.ijpddr.2019.10.003.
The PI3K and MAPK/p38 pathways control stress granule assembly in a hierarchical manner.
Heberle A, Razquin Navas P, Langelaar-Makkinje M, Kasack K, Sadik A, Faessler E
Life Sci Alliance. 2019; 2(2).
PMID: 30923191
PMC: 6441495.
DOI: 10.26508/lsa.201800257.
Therapeutic Vulnerabilities in -Mutant AML Unmasked by Palbociclib.
Uras I, Maurer B, Nebenfuehr S, Zojer M, Valent P, Sexl V
Int J Mol Sci. 2018; 19(12).
PMID: 30544932
PMC: 6321303.
DOI: 10.3390/ijms19123987.
Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.
Orellana A, Garcia-Gonzalez V, Lopez R, Pascual-Guiral S, Lozoya E, Diaz J
PLoS One. 2018; 13(1):e0189247.
PMID: 29320511
PMC: 5761851.
DOI: 10.1371/journal.pone.0189247.
Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.
Liu M, Lin Y, Zhang X, Tan Y, Yao Y, Tan J
Lab Invest. 2017; 97(11):1354-1363.
PMID: 28759011
DOI: 10.1038/labinvest.2017.70.
In vitro models of cancer stem cells and clinical applications.
S Franco S, Szczesna K, Iliou M, Al-Qahtani M, Mobasheri A, Kobolak J
BMC Cancer. 2016; 16(Suppl 2):738.
PMID: 27766946
PMC: 5073996.
DOI: 10.1186/s12885-016-2774-3.
Kinase inhibitors as potential agents in the treatment of multiple myeloma.
Abramson H
Oncotarget. 2016; 7(49):81926-81968.
PMID: 27655636
PMC: 5348443.
DOI: 10.18632/oncotarget.10745.
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
LoRusso P
J Clin Oncol. 2016; 34(31):3803-3815.
PMID: 27621407
PMC: 6366304.
DOI: 10.1200/JCO.2014.59.0018.
Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.
Xiao Z, Morris-Natschke S, Lee K
Med Res Rev. 2015; 36(1):32-91.
PMID: 26359649
PMC: 4679534.
DOI: 10.1002/med.21377.
